Relentless Placoid Chorioretinitis: A Case Series of Successful Tapering of Systemic Immunosuppressants Achieved with Adalimumab

BACKGROUND: Adalimumab, a human anti-tumor necrosis factor-ɑ monoclonal antibody, was recently reported to be effective in lowering the risk of recurrence of noninfectious uveitis. This is the first case series of adalimumab administrations for relentless placoid chorioretinitis (RPC) patients. CASE...

Descripción completa

Detalles Bibliográficos
Autores principales: Asano, Shotaro, Tanaka, Rie, Kawashima, Hidetoshi, Kaburaki, Toshikatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528075/
https://www.ncbi.nlm.nih.gov/pubmed/31143110
http://dx.doi.org/10.1159/000500077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528075/
https://www.ncbi.nlm.nih.gov/pubmed/31143110
http://dx.doi.org/10.1159/000500077

Ejemplares similares